Prognostic Values of LDH and CRP in Cervical Cancer
Han Wang1, Meng-Sen Wang2, Yong-Heng Zhou1
1Department of Oncology, Jining Cancer Hospital, Jining, Shandong, People's Republic of China.
Oncotargets and Therapy
|February 28, 2020
Summary
High levels of C-reactive protein (CRP) and lactate dehydrogenase (LDH) before and after radiotherapy, along with their ratios, are linked to poorer outcomes in cervical cancer patients. These markers indicate potential risk factors for survival.
Area of Science:
- Oncology
- Biochemistry
Background:
- Cervical cancer poses a significant threat to women's health, particularly in China.
- C-reactive protein (CRP) and lactate dehydrogenase (LDH) are recognized for their roles in tumor progression and metastasis.
Purpose of the Study:
- To investigate the correlation between pre-radiotherapy levels and pre-/post-radiotherapy ratios of CRP and LDH with overall survival (OS) in locally advanced cervical cancer patients.
- To identify CRP and LDH as potential prognostic biomarkers for cervical cancer outcomes.
Main Methods:
- Patients were stratified into groups based on pre-radiotherapy median levels of LDH and CRP.
- Further stratification was performed based on pre-/post-radiotherapy ratios of LDH and CRP.
- Kaplan-Meier curves and multivariate Cox regression analysis were used to assess overall survival and identify independent risk factors.
Main Results:
- Elevated pre-radiotherapy LDH and CRP levels were associated with significantly worse OS.
- Higher pre-/post-radiotherapy ratios of LDH and CRP also correlated with poorer overall survival outcomes.
- These findings suggest a strong link between inflammation and cellular damage markers and patient prognosis.
Conclusions:
- LDH and CRP levels and their dynamic changes during radiotherapy are significant predictors of outcomes in locally advanced cervical cancer.
- CRP and LDH serve as valuable biomarkers for assessing prognosis and guiding treatment strategies in cervical cancer management.
